Abstract:Copyright © 2021 Massachusetts Medical Society. Pulmonary hypertension is a syndrome characterized by marked remodeling of the pulmonary vasculature and a progressive rise in the pulmonary vascular load, leading to hypertrophy and remodeling of the right ventricle. Death results from right ventricular failure if pulmonary hypertension is left untreated. Pulmonary hypertension is currently defined hemodynamically by a mean pulmonary arterial pressure of higher than 20 mm Hg at rest, as measured by right heart catheterization.1 Precapillary pulmonary hypertension due to pulmonary vascular disease is further defined by an elevation in pulmonary vascular resistance of at least 3 Wood units (WU), in contrast to isolated postcapillary pulmonary hypertension, in which the pulmonary vascular resistance is less than 3 WU and the elevation in the mean pulmonary arterial pressure is due to elevated filling pressures on the left side of the heart. The several forms of pulmonary hypertension are categorized into five clinical groups (Fig. 1). This review focuses on the relatively rare form of pulmonary arterial hypertension (group 1). Immense progress has been achieved in gaining an understanding of the mechanisms, natural history, and genetic features of pulmonary arterial hypertension and in establishing targeted therapy. A full appreciation of the pathophysiology of the syndrome is important, since the diagnosis requires a thorough clinical investigation to rule out other, more common forms of pulmonary hypertension, for which treatment of the underlying disease should be the primary goal. The first anatomical description of pulmonary hypertension is credited to von Romberg.2 However, it is the advent of human right heart catheterization, first performed by Forssmann on himself in 1929,3 that led to a flurry of physiological observations on the heart and pulmonary circulation by Cournand and Richards in the 1940s. The three investigators received the Nobel Prize in Physiology or Medicine in 1956 for their seminal work. In his illuminating Nobel Lecture, Richards noted that, as a result of their collective work, ì many forms and degrees of failure were defined, and their responses to treatment measured.î 4 In 1951, Dresdale, a disciple of Cournand and Richards, and colleagues presented the first case series of patients with pulmonary hypertension of unknown cause, defined as ì primary pulmonary hypertension.î 5 Greater awareness of the disease developed in the 1960s, after an epidemic of primary pulmonary hypertension that was associated with the use of the appetite suppressant aminorex.6 This prompted the World Health Organization to convene a first meeting of pulmonary hypertension experts in 1973, to standardize the clinical and pathological nomenclature of primary pulmonary hypertension, the first attempt at an organized classification.7 The first and second meetings about pulmonary hypertension were separated by 25 years, but thereafter the World Symposium on Pulmonary Hypertension (WSPH) was convened every 5 years. The meetings brought further refinement to the classification of pulmonary hypertension, with five distinct groups Darren B. Taichman, M.D., Ph.D., Editor

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States

Global, Regional, and National Burden of Pulmonary Arterial Hypertension, 1990-2021: a Systematic Analysis of the Global Burden of Disease Study 2021

Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Pulmonary Arterial Hypertension.

The obesity paradox in pulmonary arterial hypertension: the Scottish perspective

[On the nature of the A-HEL receptors].

Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development

Evaluating the Impact of Pulmonary Arterial Hypertension Therapies on Pericardial Effusion and Patient Survival

The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease

Deregulation of BMP Signaling in the Pathogenesis of Pulmonary Hypertension

Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells.

Pulmonary Vascular Disease in Chronic Obstructive Pulmonary Disease

Health Disparities and Differences in Health-Care-Utilization in Patients With Pulmonary Arterial Hypertension

Determinants of anxiety and depression disorders among patients with pulmonary arterial hypertension

Endothelial Cell Energy Metabolism, Proliferation, and Apoptosis in Pulmonary Hypertension

Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension

Clinical Analysis of 150 Patients with Idiopathic Pulmonary Arterial Hypertension

Elevated Right Atrial Pressure Associated with Alteration of Left Ventricular Contractility and Ventricular-Arterial Coupling in Pulmonary Artery Hypertension

A magnetic anomaly associated with an albedo feature near Airy crater in the lunar nearside highlands

Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases